{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:10:06Z","timestamp":1778505006324,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhanjiang Science and Technology Development Special Fund Competitive Allocation Project","award":["2020A01023"],"award-info":[{"award-number":["2020A01023"]}]},{"name":"Zhanjiang Science and Technology Development Special Fund Competitive Allocation Project","award":["2021A05084"],"award-info":[{"award-number":["2021A05084"]}]},{"name":"Zhanjiang Science and Technology Development Special Fund Competitive Allocation Project","award":["2023A206"],"award-info":[{"award-number":["2023A206"]}]},{"name":"Zhanjiang Science and Technology Development Special Fund Competitive Allocation Project","award":["2025A501"],"award-info":[{"award-number":["2025A501"]}]},{"name":"Affiliated Hospital of Guangdong Medical University","award":["LCYJ2019A001"],"award-info":[{"award-number":["LCYJ2019A001"]}]},{"name":"Affiliated Hospital of Guangdong Medical University","award":["LCYJ2021A002"],"award-info":[{"award-number":["LCYJ2021A002"]}]},{"name":"Affiliated Hospital of Guangdong Medical University","award":["GCC2022004"],"award-info":[{"award-number":["GCC2022004"]}]},{"name":"Affiliated Hospital of Guangdong Medical University","award":["BDPAHGDMU006"],"award-info":[{"award-number":["BDPAHGDMU006"]}]},{"name":"Guangdong Medical University Clinical + Basic Science and Technology Innovation Special Program","award":["GDMULCJC2024031"],"award-info":[{"award-number":["GDMULCJC2024031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: This study compared the efficacy and safety of a single oral dose of a fixed-dose combination of netupitant and palonosetron (NEPA) with an intravenous regimen of fosaprepitant (FosAPR, 150 mg) plus palonosetron (PALO, 0.25 mg) in patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Methods: This single-center retrospective cohort study included patients with stage III\u2013IVa NPC who received cisplatin-based induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) from January 2020 to October 2025. Propensity score matching (PSM) generated 214 patients per group. All patients also received olanzapine and dexamethasone. Complete response (CR, defined as no emesis and no rescue medication), nausea control, adverse events, and nutritional status changes were assessed across the acute, delayed, overall, and extended (0\u2013168 h) phases. Results: After PSM, 214 patients were included in each group. During the first IC cycle, the oral NEPA group achieved a higher CR rate in the extended overall phase (0\u2013168 h) than the FosAPR + PALO group (80.0% vs. 70.1%, p = 0.019). A similar difference was seen in the first CCRT cycle (74.8% vs. 64.5%, p = 0.021). The advantage persisted across subsequent cycles, with no between-group difference in the acute phase. Nausea control also favored oral NEPA: rates of no significant nausea (visual analog scale &lt; 25 mm) during the extended overall phase were 77.1% versus 65.9% in the first IC cycle (p= 0.010) and 72.9% versus 60.3% in the first CCRT cycle (p = 0.006). Fewer patients in the NEPA group required rescue antiemetics (14.5% vs. 22.0% in the first IC cycle, p = 0.045), and the median time to first rescue was longer (58.3 vs. 51.3 h, p &lt; 0.001). Adverse event profiles were similar between groups, with constipation being the most common. Nutritional outcomes, including weight loss \u2265 5% and severe malnutrition, did not differ significantly. Conclusions: For patients with LA-NPC receiving highly emetogenic chemotherapy (HEC), oral NEPA appears to offer superior and sustained chemotherapy-induced nausea and vomiting (CINV) prophylaxi with a simplified administration schedule compared with the intravenous FosAPR plus PALO regimen. These findings warrant confirmation in prospective studies.<\/jats:p>","DOI":"10.3390\/cancers18101533","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:05:22Z","timestamp":1778501122000},"page":"1533","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Oral NEPA Versus Fosaprepitant Plus Palonosetron for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma: A Propensity-Score-Matched Retrospective Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Yilin","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihua","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyuan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"},{"name":"Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-2455","authenticated-orcid":false,"given":"Haiqing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal Carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.31557\/APJCP.2023.24.8.2817","article-title":"Epidemiology of Nasopharyngeal Carcinoma in Sarawak, East Malaysia","volume":"24","author":"Wong","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the Diagnosis and Treatment of Nasopharyngeal Carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/jcsm.12756","article-title":"Diagnostic Criteria for Cancer Cachexia: Reduced Food Intake and Inflammation Predict Weight Loss and Survival in an International, Multi-Cohort Analysis","volume":"12","author":"Martin","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Garutti, M., Noto, C., Past\u00f2, B., Cucciniello, L., Alajmo, M., Casirati, A., Pedrazzoli, P., Caccialanza, R., and Puglisi, F. (2023). Nutritional Management of Oncological Symptoms: A Comprehensive Review. Nutrients, 15.","DOI":"10.3390\/nu15245068"},{"key":"ref_7","first-page":"26","article-title":"2023 Updated MASCC\/ESMO Consensus Recommendations: Prevention of Radiotherapy- and Chemoradiotherapy-Induced Nausea and Vomiting","volume":"32","author":"Ruhlmann","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic Guideline Consistency and Incidence of Chemotherapy-Induced Nausea and Vomiting in US Community Oncology Practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.6004\/jnccn.2017.7043","article-title":"Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy","volume":"16","author":"Sangaralingham","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_10","first-page":"1313","article-title":"Fosaprepitant-Induced Phlebitis: A Focus on Patients Receiving Doxorubicin\/Cyclophosphamide Therapy","volume":"22","author":"Leal","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-021-01558-2","article-title":"Netupitant\/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rapoport, B.L. (2017). Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00019"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115451","DOI":"10.1016\/j.ejca.2025.115451","article-title":"Going beyond the 2023 MASCC and ESMO Guideline Update for the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting","volume":"222","author":"Jordan","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_14","first-page":"505","article-title":"Prevalence and Predictors of Long-Delayed (>120 h) Chemotherapy-Induced Nausea and Vomiting (CINV)-a Systematic Review and Individual Patient Data Meta-Analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1002\/cncr.32429","article-title":"Multicenter, Placebo-Controlled, Double-Blind, Randomized Study of Fosnetupitant in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy","volume":"125","author":"Sugawara","year":"2019","journal-title":"Cancer"},{"key":"ref_16","first-page":"9307","article-title":"Cost-Effectiveness Analysis of NEPA, a Fixed-Dose Combination of Netupitant and Palonosetron, for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: An International Perspective","volume":"30","author":"Nilsson","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103143","DOI":"10.1016\/j.critrevonc.2020.103143","article-title":"Efficacy of Intravenous NEPA, a Fixed NK1\/5-HT3 Receptor Antagonist Combination, for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) during Cisplatin- and Anthracycline Cyclophosphamide (AC)-Based Chemotherapy: A Review of Phase 3 Studies","volume":"157","author":"Aapro","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","article-title":"Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)","volume":"10","author":"Hata","year":"2022","journal-title":"Oncol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A Randomized Phase III Study Evaluating the Efficacy and Safety of NEPA, a Fixed-Dose Combination of Netupitant and Palonosetron, for Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hed.25982","article-title":"Radiation-Induced Nausea and Vomiting in Head and Neck Cancer: Is It Something Worth Considering in the Intensity Modulated Radiotherapy Era? \u201cA Narrative Review.\u201d","volume":"42","author":"Paiar","year":"2020","journal-title":"Head. Neck"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.prro.2013.08.003","article-title":"Dorsal Vagal Complex of the Brainstem: Conformal Avoidance to Reduce Nausea","volume":"4","author":"Monroe","year":"2014","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jcsm.13196","article-title":"Effects of Induction Chemotherapy on Nutrition Status in Locally Advanced Nasopharyngeal Carcinoma: A Multicentre Prospective Study","volume":"14","author":"Miao","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.ejcn.1601412","article-title":"Use of the Scored Patient-Generated Subjective Global Assessment (PG-SGA) as a Nutrition Assessment Tool in Patients with Cancer","volume":"56","author":"Bauer","year":"2002","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000332914","article-title":"Role of Nutritional Status in Predicting the Length of Stay in Cancer: A Systematic Review of the Epidemiological Literature","volume":"59","author":"Gupta","year":"2011","journal-title":"Ann. Nutr. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0959-8049(05)80075-9","article-title":"Course, Patterns, and Risk-Factors for Chemotherapy-Induced Emesis in Cisplatin-Pretreated Patients: A Study with Ondansetron","volume":"28","author":"Meerpohl","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"oyae233","DOI":"10.1093\/oncolo\/oyae233","article-title":"Comparative Effectiveness of Netupitant-Palonosetron plus Dexamethasone versus Aprepitant-Based Regimens in Mitigating Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials","volume":"30","author":"Luo","year":"2024","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.annonc.2025.10.017","article-title":"Personalised Antiemetic Prophylaxis with NEPA for Patients at High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial","volume":"37","author":"Molassiotis","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_28","first-page":"e38301","article-title":"The Incidence and Severity of Patient-Reported Side Effects of Chemotherapy in Routine Clinical Care: A Prospective Observational Study","volume":"15","author":"Katta","year":"2023","journal-title":"Cureus"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Maria, O.M., Eliopoulos, N., and Muanza, T. (2017). Radiation-Induced Oral Mucositis. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00089"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jand.2015.10.020","article-title":"Chemotherapy-Induced Nausea and Vomiting: A Narrative Review to Inform Dietetics Practice","volume":"116","author":"Marx","year":"2016","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN Practical Guideline: Clinical Nutrition in Cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","article-title":"Phase III Safety Study of Intravenous NEPA: A Novel Fixed Antiemetic Combination of Fosnetupitant and Palonosetron in Patients Receiving Highly Emetogenic Chemotherapy","volume":"29","author":"Schwartzberg","year":"2018","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1533\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:23:27Z","timestamp":1778502207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101533"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101533","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]}}}